drugset / Trial / NCT03323710
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The study aims to assess antineoplastic efficacy, safety, influence on quality of life and disease-related stress of propranolol taken in combination with sunitinib in previously untreated metastatic renal cell carcinoma
Timeline
- Start
- 2018-09
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Propranolol | Small molecule | 40 mg | Oral |
| Subject | Propranolol | Small molecule | 80 mg | Oral |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |